Search Medical Condition
Please enter condition
Please choose location

Plainfield, Indiana Clinical Trials

A listing of Plainfield, Indiana clinical trials actively recruiting patient volunteers.

RESULTS

Found (44) clinical trials

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream 1% in Subjects With Facial Acne Vulgaris (25)

The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.

Phase

0.0 miles

Learn More »

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

The study will consist of four phases: Screening Phase - up to 35 days Double-blind Placebo-controlled Phase- Weeks 0 to 16 Subjects will receive treatment with one of the following: apremilast 30 mg tablets orally BID or placebo tablets (identical in appearance to apremilast 30 mg tablets) orally BID Apremilast ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

This is a randomized, multicenter, double-blind, vehicle-controlled, 2 arm study to evaluate the safety and efficacy over 12 weeks of FMX101 topical foam containing 4% minocycline compared to vehicle in the treatment of subjects with moderate-to-severe facial acne vulgaris. Qualified subjects will be randomized to receive 1 of the following ...

Phase

0.0 miles

Learn More »

The purpose of this study is to evaluate the efficacy of each strength of INCB018424 cream once daily or twice daily in subjects with atopic dermatitis compared with vehicle cream.

Phase

0.0 miles

Learn More »

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)

Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD). Secondary objectives: To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, and health-related quality of life ...

Phase

0.0 miles

Learn More »

Safety Efficacy and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

To characterize the efficacy, safety and tolerability of SNA-120 at 2 doses versus placebo when administered topically for the treatment of pruritus associated with psoriasis vulgaris (PV) and PV itself.

Phase

0.19 miles

Learn More »

A Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis

The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in patients with moderate-to-severe atopic dermatitis.

Phase

0.19 miles

Learn More »

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.

Phase

0.19 miles

Learn More »

Study Of PF-06817024 In Healthy Subjects In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

The purpose of the study for Part 1 is to evaluate the safety and tolerability of PF-06817024 in healthy subjects. The purpose of the study for Part 2 is to evaluate the safety and tolerability of PF-06817024 in patients with chronic rhinosinusitis with nasal polyps. The purpose of the study ...

Phase

1.11 miles

Learn More »

Evaluate the Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects (Ages 2 to 11 Years Inclusive) With Mild to Moderate Plaque Psoriasis.

This is a multicenter, open-label, Phase 1 study in a total of 75 pediatric subjects, ages 2 to 11 years, inclusive, with mild or moderate plaque psoriasis. The study will enroll sufficient subjects with plaque psoriasis and an ISGA score of mild to moderate (score of 2 or 3) at ...

Phase

1.11 miles

Learn More »